Friday, November 08 2019
Molecular Research, Nerve Regeneration, and Cell Manufacturing Lead Local Industry Growth
New Orleans, LA -- Governor John Bel Edwards and New Orleans Mayor LaToya Cantrell announced expansions by three biotech firms – AxoSim, Cadex Genomics and Obatala Sciences – that will create 135 new direct jobs at the University of New Orleans and the New Orleans BioInnovation Center, a biotech incubator where all three firms launched local startup operations.
AxoSim’s innovative neuroscience drug discovery platforms are based upon technology licensed from Tulane University. The company will expand its existing facilities at the BioInnovation Center, and AxoSim projects adding 75 jobs at an average annual salary of $60,000, plus benefits.
Thursday, September 26 2019
$75 million capital investment will create 145 life-science jobs in the region
Madison, WI -- Catalent Biologics’ cell line development and biomanufacturing site in Madison is expanding with a $75 million investment expected to create at least 145 new jobs by the end of 2021, Governor Tony Evers, local leaders and company officials announced.
“We are grateful Catalent has decided to continue investing in Wisconsin and create opportunities in Madison,” said Governor Evers. “The numerous high-paying jobs created by this expansion will require an educated workforce to support new roles, which provides another example of how backing education in Wisconsin creates opportunities for businesses to grow and utilize our strong workforce.”
Friday, December 21 2018
Hickory, NC -- A German group of specialized radiopharmaceutical companies has selected Hickory, North Carolina, for the first North American manufacturing plant of its subsidiary Isotopes Technologies Garching, creating 137 new well-paying jobs.
The parent company Isotopen Technologien München AG (ITM), based in Garching near Munich, will invest $12 million in Catawba County. ITM develops, produces and supplies innovative diagnostic and therapeutic radionuclides and radiopharmaceuticals. Some of ITM’s products are part of a new generation of targeted cancer diagnostics and therapies.
“Establishing our first North American facility is a remarkable milestone for our company and we are very excited,” said Steffen Schuster, CEO of ITM. “This enables us to achieve further growth and to be closer to our U.S. customers providing advanced targeted radiotherapeutics, which are likely to create enormous opportunities in cancer treatment.”
Tuesday, August 15 2017
Hundreds of Farmers, Area Leaders Join Poet CEO in Commemorating Start of Construction, New Jobs, New Grain Demand
Marion, OH -- POET Biorefining – Marion broke ground today to expand its production capacity from 70 million gallons per year to 150 million gallons per year. The project will also increase production of dried distillers grains from the current 178,000 tons annually to 360,000 tons. With the groundbreaking, site work has officially begun, with project completion slated for Q3 of 2018.
“This expansion will add 26 million bushels of new corn demand annually for the local area and create new jobs and economic activity for rural Ohio," POET CEO Jeff Broin said. “In recent years, I know farmers are struggling with low commodity prices, which is creating lower farm incomes and decreasing land values. Biofuels have been the only real growth sector for ag commodities in the past decade. We will need to see biofuels increase as a percentage of the US and world fuel supply, and as a percentage of our gas tanks to stabilize worldwide ag prices and land values. We are excited that the Marion plant expansion can play a small role in this important arena."